Toxicities Following Treatment with Bisphosphonates and Receptor Activator of Nuclear Factor-κB Ligand Inhibitors in Patients with Advanced Prostate Cancer-Reference-Cited by-同舟云学术

Toxicities Following Treatment with Bisphosphonates and Receptor Activator of Nuclear Factor-κB Ligand Inhibitors in Patients with Advanced Prostate Cancer

Published:2014-02 Issue:2 Volume:65 Page:278-286
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Gartrell Benjamin A.,Coleman Robert E.,Fizazi Karim,Miller Kurt,Saad Fred,Sternberg Cora N.,Galsky Matthew D.

Publisher

Elsevier BV

Subject

Urology

Reference50 articles.

1. Cancer statistics, 2012;Siegel;CA Cancer J Clin,2012

2. Estimates of cancer incidence and mortality in Europe in 2008;Ferlay;Eur J Cancer,2010

3. Spread of prostatic cancer to bone;Jacobs;Urology,1983

4. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006;Sathiakumar;Prostate Cancer Prostatic Dis,2011

5. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis;Snedecor;J Med Econ,2013

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of osteoclast inhibitors in prostate cancer bone metastasis; a narrative review;Journal of Oncology Pharmacy Practice;2024-08-22

2. Basic-helix-loop-helix family member e41 suppresses osteoclastogenesis and abnormal bone resorption disease via NFATc1;iScience;2024-03

3. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials;Signal Transduction and Targeted Therapy;2022-06-24

4. Targeted Radionuclide Therapy for Bone Metastasis;Nuclear Oncology;2022

5. Bone metastases—current status of bone-targeted treatments;Bone Cancer;2022